Related references
Note: Only part of the references are listed.Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)
Matthew J. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Pre-operative Endocrine Therapy
Laura M. Arthur et al.
CURRENT BREAST CANCER REPORTS (2017)
Treatment strategy for metastatic breast cancer with estrogen receptor-positive tumor
Hirotaka Iwase
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2015)
Optimum duration of neoadjuvant letrozole to permit breast conserving surgery
Robert Carpenter et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients - A phase II trial
Duveken B. Y. Fontein et al.
EUROPEAN JOURNAL OF CANCER (2014)
Use of the neo-adjuvant exemestane in post-menopausal estrogen receptor-positive breast cancer: A randomized phase II trial (PTEX46) to investigate the optimal duration of preoperative endocrine therapy
Takashi Hojo et al.
BREAST (2013)
Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study
E. Alba et al.
ANNALS OF ONCOLOGY (2012)
Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR[ plus ] operable breast cancer
Antonio Llombart-Cussac et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2012)
Neoadjuvant endocrine therapy of breast cancer: which patients would benefit and what are the advantages?
Hiroyuki Takei et al.
BREAST CANCER (2011)
Increase in response rate by prolonged treatment with neoadjuvant letrozole
J. Michael Dixon et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer:: A phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy
Ute E. Krainick-Strobel et al.
BMC CANCER (2008)
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics
Matthew J. Ellis et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Multicenter phase II trial of neoadjuvant exemestane for postmenopausal patients with hormone receptor-positive, operable breast cancer: Saitama Breast Cancer Clinical Study Group (SBCCSG-03)
Hiroyuki Takei et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer
Vladimir F. Semiglazov et al.
CANCER (2007)
Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer
Mitch Dowsett et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer - The Pre-Operative Arimidex Compared to Tamoxilen (PROAC7) trial
L Cataliotti et al.
CANCER (2006)
Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus)
D Hind et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2006)
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial
IE Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer:: Evidence from a phase III randomized trial
MJ Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
